A Phase 2 interventional study of Niacinamide and Placebo in Ischemia Reperfusion Injury, Myocardial Injury and Acute Kidney Injury, sponsored by Kaiser Permanente. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Kaiser Permanente · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Reperfusion Injury with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Reperfusion Injury · United States.
Among the 44 studies in Reperfusion Injury with a site in United States, this one is the 4th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2021, is one of 11 in phase 2, and was the 39th registered.
260 studies on the registry are indexed under Reperfusion Injury; 43 are open to participants now.
Browse Reperfusion Injury studies →5 of the 44 studies in Reperfusion Injury with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Boston Children's Hospital · Sites in United States
Rhode Island Hospital · Sites in United States
Ages 18–75
Gary Van Guilder · Sites in United States
Ages 18–65 · Healthy volunteers
Mitovation, Inc · Sites in United States
Ages 48 hrs–1 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Reperfusion Injury studies recruiting now, 16 (57%) set no upper age limit and 7 (25%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 18 · Phase 3 7 · Phase 4 1
First in 1997; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 331 is above the median of 60 across 212 interventional studies indexed under Reperfusion Injury.
Median enrollment 30 across the 39 interventional studies, 20 across the 5 observational. Of the 32 that completed or were terminated, 13 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 44 have an industry lead sponsor. The 10 most frequent:
Kaiser Permanente is the lead sponsor of 393 studies on the registry; 43 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
Kaiser Permanente has 1 study filed under Reperfusion Injury — fewer than ten, so there is no comparison to draw.
3 of the studies in Reperfusion Injury with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03663543University of PennsylvaniaIntravenous Estrogen in Kidney Transplant Study | 2027-01-31 |
| NCT05574296Boston Children's HospitalHydrogen's Feasibility and Safety as a Therapy in ECPR | 2027-03-31 |
| NCT07385651Vanderbilt University Medical CenterDeceased Donor Kidney Storage at 10 Celsius Versus Conventional Storage | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 44 studies in Reperfusion Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery
This trial is a single-center, randomized, double-blind placebo-controlled Trial of Nam versus placebo in patients undergoing on-pump cardiac surgery. After screening and enrollment, patients will be stratified according to CKD status (eGFR\<45 ml/min/m2) and surgical site and randomized in a 1:1 manner to receive either Nam 3 grams or placebo on the day of surgery and post-surgical days one and two.
The overall trial duration is planned for 42 months, consisting of 39 months of active recruitment and treatment period and three months of follow-up from the last patient enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Procedures include:
Risk factors for surgery related to adverse cardiovascular outcomes include one or more of the following:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Niacinamide
Drug: Placebo
Niacinamide 3 grams on the day of surgery and post-surgical days one and two
Matched placebo on the day of surgery and post-surgical days one and two
Troponin T AUC
Troponin T AUC, composed of single daily serum measurements
Time frame: From baseline to three days after surgery
Mean difference in uQuin/Tryp ratio AUC
Mean difference in uQuin/Tryp ratio AUC composed of single daily serum measurements
Time frame: From baseline to three days after surgery
Mean difference in eGFR
Mean difference in eGFR (CKD-EPI formula)
Time frame: From baseline through day 5.
Number of Participants with the following Adverse Events and Serious Adverse Events
* Postoperative dysrhythmias * Postoperative re-hospitalization. * Heart failure * Surgical wound infection * Transfusion requiring perioperative bleed * Post-surgical deep vein thrombosis and pulmonary emboli * Nosocomial infection * Nausea and vomiting * Adverse events leading to treatment discontinuation * Perioperative liver injury (x2 upper normal-limit) * Post-operative thrombosis and pulmonary emboli * Impairment of renal function (KDIGO AKI)
Time frame: From baseline through day 90
Length of index hospital stay.
• Mean length of index hospital stay (days)
Time frame: From baseline through day 90
Length of intensive care unit stay.
• Mean length of intensive care unit stay (days)
Time frame: From baseline through day 90
Perioperative inotropic-score and vasoactive-inotropic score.
• Mean inotropic-score and vasoactive-inotropic score
Time frame: At 6, 12, 24, and 48 hours post operatively
Perioperative fluid volume administration.
• Mean daily perioperative fluid volume administration
Time frame: From baseline through day 2
Perioperative brain-natriuretic peptide AUC
BNP AUC, composed of single daily serum measurements
Time frame: From baseline to three days after surgery
Plan to share: No
Ran from Sep 2021 to primary completion in Jun 2026, 57 months.
Of 18 phase 2 interventional studies under Reperfusion Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's 57 months is above that.
Primary completion moved twice since we started tracking on Sep 25, 2026: Apr 2025 → Jun 2026, last on Oct 26, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Jun 2025 → Jun 2026, last on Oct 26, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niacinamide